Chulalongkorn University to start human trials for its Covid-19 vaccine
The vaccine research centre at Chulalongkorn University is planning to start human trials of its mRNA vaccine candidate, called Chula – Cov19, in April. The university received prototype vaccines from factories in the United States. If the human trials are effective, the first million doses of locally-produced vaccines could available this year.
According to the centre’s director Dr. Kiat Ruxrungtham, the human trials will be conducted on 72 volunteers to assess the right dosages. The second stage of efficacy and safety is expected to be performed on about 600 volunteers from June until September.
He also says that the centre’s mRNA vaccines can be stored at 5◦C, compared to the Pfizer vaccine that must be well kept at below -70◦C. Therefore, the Thai-made vaccine is expected to be easier and more convenient for storage management. However, there will be a test to find the right temperature for the vaccine storage.
The Chula – Cov19 vaccine development project a collaboration between Chulalongkorn University’s vaccine research centre and Pennsylvania University in the US. The centre’s research team has been studying several vaccine candidates since the Covid-19 outbreak last year.
SOURCE: Thai PBS World | Chulalongkorn Hospital
